Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Erythropoietin and Cognition During Hypoglycaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes~* Hypoglycaemia unawareness~* 2 or more episodes of hypoglycaemia in the last 12 months~* Age \>18 år~* Duration of diabetes \> 5 år~* Weight \> 50 kg~* No pregnancy~* Informed consent~Exclusion Criteria:~* Pregnancy~* Heart failure (NYHA 2-4)~* Ischaemic heart disease~* Epilepsy~* Venous thromboembolic disease~* Thrombocytosis~* Beta receptor antagonists~* Disturbance of vision~* History of stroke~* History of erythropoietin treatment~* Plasma-creatinin \> 100 umol/l (male)or 88 umol/l (female)~* Plasma-haemoglobin \< 7,0 or \> 11 mmol/l at time of inclusion~* Operation with blood loss within the last 6 weeks~* Cancer~* Treated with ciclosporin~* Suspicion of non-compliance with protocol~* Conditions incompatible with participation - e.g. safety considerations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Isotonic NaCl, intravenously injection
- Active (Type: EXPERIMENTAL): Epoetin alfa, injected

Based on this trial design, predict the completion outcome and termination type (if applicable).